Additionally, another HDAC inhibitor, entinostat, has shown anti-cancer activity in both in vitro and in vivo models of gastroenteropancreatic neuroendocrine tumors, where tumor growth significantly decreased by up to 68% of its original size since the beginning of the clinical trial [269]. This evidence concerns the gene HDAC9 and cancer.